Company Filing History:
Years Active: 2024
Title: Jieun Min: Innovator in Pharmaceutical Chemistry
Introduction
Jieun Min is a notable inventor based in Suwon-si, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative patents. With a total of 2 patents, Min's work focuses on developing novel compounds that have potential therapeutic applications.
Latest Patents
One of Jieun Min's latest patents is titled "Thiazole derivatives and pharmaceutically acceptable salts thereof." This invention provides a novel thiazole derivative or a pharmaceutically acceptable salt, along with a method for its preparation. The thiazole derivative exhibits selective inhibitory activity against cyclin-dependent kinase (CDK), making it a promising candidate for preventing or treating various diseases associated with CDK. Another significant patent is the "SHP2 inhibitor and use thereof." This invention relates to an inhibitor of SHP2, along with a pharmaceutical composition for preventing or treating diseases related to SHP2. The invention outlines methods for treatment and prevention, showcasing its potential effectiveness in addressing SHP2-related diseases.
Career Highlights
Throughout his career, Jieun Min has worked with reputable companies in the pharmaceutical industry. Notably, he has been associated with Kanaph Therapeutics Inc. and Yungjin Pharm Co., Ltd. His work in these organizations has contributed to advancements in drug development and therapeutic solutions.
Collaborations
Jieun Min has collaborated with several professionals in his field, including Mijung Lee and Kangwoo Lee. These collaborations have likely enhanced his research and development efforts, leading to innovative solutions in pharmaceutical chemistry.
Conclusion
Jieun Min's contributions to pharmaceutical chemistry through his patents highlight his role as an innovator in the field. His work on thiazole derivatives and SHP2 inhibitors demonstrates the potential for new therapeutic agents that can address significant health challenges.